Table 3.
Baseline characteristics of study subjects stratified by time-averaged serum uric acid levels.
| Uric acid < 6.77 (N = 67) | 6.77 ≤ Uric acid <7.64 (N = 67) | Uric acid ≥ 7.64 (N = 67) | P | |
|---|---|---|---|---|
| Time to aunria(months) | 16.44 ± 9.02 | 24.53 ± 17.09 | 15.71 ± 9.12 | 0.005** |
| sex (male%) | 48.80 | 48.60 | 46.20 | 0.136 |
| age(year) | 45.77 ± 15.15 | 48.62 ± 14.53 | 53.67 ± 12.77 | 0.113 |
| BMI(kg/m2) | 21.88 ± 4.00 | 21.56 ± 4.86 | 22.50 ± 4.02 | 0.111 |
| Diabetes (%) | 30.85 | 26.08 | 28.36 | 0.326 |
| Cardiovascular disease (%) | 34.31 | 36.92 | 37.31 | 0.487 |
| Etiology (%) | ||||
| Glomerulonephritis | 63.08 | 56.92 | 56.72 | 0.116 |
| Diabetic nephropathy | 21.54 | 21.54 | 20.90 | 0.206 |
| Hypertension | 2.3 | 2.4 | 2.6 | 0.341 |
| Other | 12.31 | 12.50 | 16.42 | 0.124 |
| Medication | ||||
| ACE inhibitors or ARBs (%) | 64.62 | 67.69 | 75.76 | 0.597 |
| a-block (%) | 53.85 | 39.06 | 56.06 | 0.605 |
| β-block (%) | 63.08 | 62.5 | 66.67 | 0.371 |
| Calcium channel blockers (%) | 80.00 | 86.56 | 85.39 | 0.056 |
| Diuretics (%) | 46.15 | 51.56 | 43.33 | 0.086 |
| VDRAs (%) | 43.08 | 56.25 | 39.39 | 0.631 |
| PBAs (%) | 49.70 | 40.63 | 53.03 | 0.478 |
| Statin (%) | 27.69 | 34.38 | 18.18 | 0.094 |
| Uric acid-lowering drug (%) | 10.80 | 10.90 | 10.60 | 0.546 |
| PD-related parameters | ||||
| Weekly Kt/V urea | 2.45 ± 0.94 | 2.45 ± 0.48 | 2.21 ± 0.61 | 0.066 |
| KT/V urea for PD | 1.558 ± 0.43 | 1.58 ± 0.49 | 1.59 ± 0.39 | 0.221 |
| KT/V urea for RRF | 0.62 ± 0.44 | 0.72 ± 0.42 | 0.65 ± 0.51 | 0.506 |
| D/P at 4 hrs | 0.64 ± 0.15 | 0.66 ± 0.19 | 0.70 ± 0.15 | 0.247 |
| ultrafiltration (L/d) | 0.29 ± 0.46 | 0.20 ± 0.50 | 0.17 ± 0.37 | 0.343 |
| Hemoglobin(g/dL) | 8.20 ± 2.38 | 8.40 ± 2.85 | 8.00 ± 2.80 | 0.400 |
| Albumin(g/dL) | 3.49 ± 0.63 | 3.57 ± 0.75 | 3.65 ± 0.61 | 0.445 |
| BUN(mmol/L) | 28.24 ± 15.45 | 29.85 ± 13.60 | 27.38 ± 12.22 | 0.055 |
| Creatinine(mg/dL) | 9.99 ± 4.34 | 10.39 ± 4.17 | 10.45 ± 3.89 | 0.066 |
| Calcium(mg/dL) | 8.36 ± 1.12 | 8.08 ± 1.11 | 8.12 ± 1.16 | 0.233 |
| Phosphorus(mg/dL) | 6.18 ± 1.77 | 6.35 ± 1.86 | 6.56 ± 1.91 | 0.052 |
| Cholesterol(mmol/L) | 4.50 ± 1.28 | 4.89 ± 1.40 | 5.57 ± 1.04 | 0.483 |
| Triglyceride(mmol/L) | 1.63 ± 1.07 | 1.78 ± 0.78 | 1.85 ± 1.08 | 0.440 |
| Bicarbonate(mEq/L) | 19.29 ± 3.83 | 19.98 ± 4.06 | 18.03 ± 4.65 | 0.148 |
| Baseline Uric acid(mg/dL) | 8.34 ± 3.04 | 8.42 ± 3.09 | 8.57 ± 3.10 | 0.066 |
| iPTH(pg/mL) | 441.76 ± 39.33 | 451.21 ± 37.66 | 437.02 ± 34.34 | 0.358 |
| Ferritin(ng/L) | 374.95 ± 46.56 | 311.54 ± 33.24 | 400.78 ± 41.40 | 0.093 |
| Initial RRF (L/min/1.73m2) | 5.72 ± 1.07 | 5.27 ± 1.96 | 5.52 ± 2.02 | 0.063 |
| CRP(mg/L) | 3.4 ± 5.4 | 3.3 ± 5.6 | 3.5 ± 5.7 | 0.683 |
| RRF loss during 5 years (%) | 46.15 | 30.77 | 50.75 | 0.021* |
BMI = body mass index, DM = diabetes, CVD = cerebrovascular disease, RRF = residual renal function, PBAs, phosphate binding agents; VDRAs = Vitamin D receptor activators.